RESEARCH ARTICLE

Preoperative dynamic breast magnetic resonance imaging kinetic features using computer-aided diagnosis: Association with survival outcome and tumor aggressiveness in patients with invasive breast cancer

Sang Yu Nam¹, Eun Sook Ko²*, Yaeji Lim³, Boo-Kyung Han², Eun Young Ko², Ji Soo Choi², Jeong Eon Lee⁴

¹ Department of Radiology, Gachon University Gil Medical Center, Gachon University of Medicine and Science, Incheon, Korea, ² Department of Radiology, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul, Korea, ³ Department of Applied Statistics, Chung-Ang University, 84 Heukseok-ro, Dongjak-gu, Seoul, Korea, ⁴ Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul, Korea

* mathilda0330@gmail.com

Abstract

Objectives

To evaluate whether preoperative breast dynamic contrast-enhanced (DCE) magnetic resonance (MR) imaging kinetic features, assessed using computer-aided diagnosis (CAD), can predict survival outcome and tumor aggressiveness in patients with invasive breast cancer.

Materials and methods

Between March and December 2011, 301 women who underwent preoperative DCE MR imaging for invasive breast cancer, with CAD data, were identified. All MR images were retrospectively evaluated using a commercially available CAD system. The following kinetic parameters were prospectively recorded for each lesion: initial peak enhancement, the proportion of early phase medium and rapid enhancement, and the proportion of delayed phase persistent, plateau, and washout enhancement. The Cox proportional hazards model was used to determine the association between the kinetic features assessed by CAD and disease-free survival (DFS). The peak signal intensity and kinetic enhancement profiles were compared with the clinical-pathological variables.

Results

There were 32 recurrences during a mean follow-up time of 55.2 months (range, 5–72 months). Multivariate analysis revealed that a higher peak enhancement (DFS hazard ratio, 1.004 [95% confidence interval (CI): 1.001, 1.006]; P = .013) on DCE MR imaging and a triple-negative subtype (DFS hazard ratio, 21.060 [95% CI: 2.675, 165.780]; P = .004) were
associated with a poorer DFS. Higher peak enhancement was significantly associated with a higher tumor stage, clinical stage, and histologic grade.

Conclusions
Patients with breast cancer who showed higher CAD-derived peak enhancement on breast MR imaging had worse DFS. Peak enhancement and volumetric analysis of kinetic patterns were useful for predicting tumor aggressiveness.

Introduction
Dynamic contrast-enhanced (DCE) magnetic resonance (MR) imaging is the most sensitive modality for breast cancer detection, and is commonly used for the preoperative evaluation of newly diagnosed breast cancer cases [1–3]. Morphological features and patterns of contrast enhancement on MR imaging provide important information, not only of tumor histological features, such as vascularization, but also survival outcome prediction [4–6].

Regarding evaluating kinetic features, there are several methods to assess the kinetic enhancement patterns of breast tumor obtained from DCE MR imaging [7]. For quantitative analysis, pharmacokinetic models, such as Tofts and extended Tofts models, are standard for analyzing DCE MRI data. These models are suitable when the tissue under investigation is weakly vascularized or in the presence of a negligible intravascular concentration of contrast agent [8, 9]. The Tofts model considers intravascular space as one compartment and extracellular extravascular space as the other compartment, excluding the functionality of intravascular space. Computation of pharmacokinetic parameters requires curve fitting to concentration–time curves for multiple voxels. This is typically time-consuming and hinders online access of pharmacokinetic maps by radiologists [10]. Most commonly, breast kinetic enhancement patterns are measured semi-quantitatively using modest temporal resolution with at least two to three post-contrast T1-weighted acquisitions, with k-space centered at approximately 90–120 seconds after contrast injection for the first post-contrast images [7]. Using the data obtained at each of these time points, a time-signal intensity curve can be determined for a given lesion or region of interest. Despite its high utility in functional analysis, kinetic assessment using a manually drawn region of interest (ROI) is limited because it only reflects partial pixel information of the lesion. Moreover, ROI placement and interpretation are operator-dependent and time-consuming.

Despite the controversy of whether it improves the diagnostic performance of MR imaging, computer-aided diagnosis (CAD) systems have the advantage of being easy to use, and are widely clinically available to automatically assess kinetic information and perform volumetric analysis for breast lesions [11–14]. CAD systems eliminate the need for labor-intensive tasks, such as manual drawing of ROI by a technician or radiologist. In addition, CAD has the potential to increase observer reproducibility in DCE MR imaging by performing automatic and quantitative analysis of the contrast material uptake [15–17].

The correlation between kinetic parameters on CAD and the histological characteristics of breast cancer have been evaluated [18]. CAD-derived kinetic information may be used to assess tumor aggressiveness, including hormone receptor status and histologic grade. In terms of survival outcomes, Yi et al. [19] reported that a smaller reduction in the washout component on DCE MR imaging assessed using CAD after neoadjuvant chemotherapy (NAC) in breast cancer patients was independently associated with a worse recurrence-free survival (RFS) and...
overall survival [19]. In a preoperative setting, Dietzel et al. [20] evaluated the potential of DCE MR imaging to predict disease-related death using CAD on 115 patients, finding that total tumor volume, initial peak enhancement, and time to peak enhancement showed a negative correlation with survival. The persistent curve type, however, showed a positive correlation with survival. Baltzer et al. [21] analyzed the enhancement kinetics of 59 patients using CAD and found that a washout component could be identified as a significant and independent predictor of distant metastasis occurrence. However, because their studies only included a small sample size, patients in NAC setting, or a qualitative assessment using in-house software, there is currently a lack of reports evaluating the correlation between preoperative MR imaging kinetic parameters assessed using a commercially available CAD with recurrence outcomes in patients with breast cancer.

Therefore, the purpose of our study was to evaluate whether the kinetic features of preoperative MRI, assessed using CAD, can predict survival outcomes in patients with newly diagnosed invasive breast cancer.

**Materials and methods**

**Patients**

This retrospective study was approved by the Institutional Review Board of the Samsung Medical Center (SMC IRB 2017-03-057) and waived the need for informed patient consent. Between March and December 2011, 823 consecutive women (mean age of 50 years, range 24–85 years) who had undergone surgery for invasive breast cancer were identified. The inclusion criteria for our study were as follows: (a) completion of preoperative DCE MR imaging with CAD at our institution, (b) initial unilateral breast biopsy-proven malignancy with a final pathologic diagnosis of invasive breast carcinoma, (c) a lesion manifesting as a mass on MR imaging. We identified 753 invasive breast carcinomas that met these criteria. We excluded cases where MR imaging was performed after diagnosis by vacuum-assisted or excisional biopsy (n = 97), those who underwent breast MR imaging with a 3-T scanner (n = 264), and those who had a follow-up period of less than 3 months (n = 10) were also excluded. To exclude any magnetic strength effects during the MR examination, we only included patients who underwent 1.5-T MRI, ensuring that the MR images were obtained under homogeneous conditions. Finally, 301 women, aged 26–80 years (mean age 51 years) were included in our study. S1 Dataset provides detailed characteristics of patients (online). The mean interval between preoperative MR examination and surgery was 13 days (range 1–37 days).

**MR imaging protocol**

MR imaging was performed using a 1.5-T system (Achieva; Philips Medical Systems, Best, The Netherlands) with a dedicated bilateral phased-array breast coil, with the patient in a prone position. The MR imaging examination consisted of turbo spin-echo T1- and T2-weighted sequences, and a three-dimensional DCE sequence. The DCE MR imaging sequences were performed using the following parameters: repetition time (TR) = 6.5 ms, echo time (TE) = 2.5 ms, slice thickness = 1.5 mm, flip angle = 10’, matrix size = 376 × 374 mm, field of view (FOV) = 32 × 32 cm. Axial DCE MR imaging was performed using 1 precontrast and 6 postcontrast dynamic series. Contrast-enhanced images were acquired 30, 90, 150, 210, 270, and 330 seconds after the contrast material injection. The length of each dynamic series was 60.05 seconds. A 0.1 mmol/kg bolus of gadobutrol (Gadovist; Bayer Healthcare Pharmaceutical, Berlin, Germany) was injected for dynamic contrast imaging, before a 20-mL saline flush.
Assessment of MR imaging and computer-aided diagnosis

The DCE MR images were transferred to a CAD system (CADstream, version 4.1.3, Merge Healthcare, Chicago, IL, USA) that analyzed the signal intensities within each voxel of the FOV obtained during the dynamic sequences. The American College of Radiology Breast Imaging Reporting and Data System (ACR BI-RADS) MR lexicon [22] defined a persistent kinetic pattern as a continuous increase in signal over time. A plateau is defined as a signal intensity that does not change over time, after an initial rise. When the signal intensity decreases by more than 10%, after its highest point following its initial rise, it is defined as a washout. Using CAD stream, a color overlay showing the changes in signal intensity over time was automatically generated in all slices using a predefined minimum threshold. We defined the minimum threshold as 50%, or a greater increase in pixel-by-pixel comparison between the precontrast and second post-contrast images. When the relative enhancement increase was more than 100% of the precontrast image, it was classified as “rapid uptake,” and when it was 50–100% it was classified as “medium uptake.” When the signal intensity continued to show an increase of more than 10% in the sixth postcontrast-enhanced images, compared to the second postcontrast-enhanced images, it was classified as “persistent.” When the signal intensity showed a decrease of more than 10%, it was classified as a “washout,” and when the signal intensity continued to show within a 10% range, it was classified as a “plateau.” We maintained a single threshold value for early and delayed phase enhancements across all patients. Volumetric assessment of the kinetic components refers to the assessment of the percentage volume of each kinetic component found within the tumors at both early and delayed phases of enhancement. The CAD reports included the following kinetic features: the initial peak enhancement values, proportions of early phase medium and rapid enhancements, and the proportion of delayed phase persistent, plateau, and washout enhancements. The following three kinetic curve patterns presented by CAD were also included in the CAD reports: type 1, delayed persistent enhancement pattern; type 2, delayed plateau enhancement pattern; and type 3, delayed washout enhancement pattern. The CAD reports were stored prospectively by interpreting radiologists, and square ROI of the entire tumor was automatically segmented when an operator chose the image slice showing the largest diameter. For cases that had multiple cancers on the MRI, we used the values of the index cancer.

The MR imaging findings were retrospectively evaluated according to BI-RADS MR lexicon [22] by two board-certified radiologists (S.Y.N., E.S.K., with 6 and 10 years of experience in breast MR imaging, respectively, in consensus. In cases with discrepancy in interpretation between the two readers, a third radiologist (J.S.C. with 7 years of experience in breast MR imaging) reviewed the images to reach a consensus. The radiologists assessed the shape (oval, round, or irregular), margin (circumscribed, irregular, or spiculated), and internal enhancement characteristics (homogeneous, heterogeneous, rim, or dark internal septation) of each mass.

Histopathological features

The following parameters of the pathological reports of either breast-conserving surgery or mastectomy specimens were reviewed: pathologic diagnosis, histologic grade, surgical margin status, presence of an extensive intraductal component (EIC), lymphovascular invasion (LVI), estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2), and Ki-67 expression status. Positivity for ER and PR was defined using a cut-off value of greater than 1% positively stained nuclei. Immunohistochemical HER2 scores of 3+ (strong homogeneous staining) were considered positive. In cases of HER2 scores of 2+, HER2 gene amplification was confirmed using silver in situ hybridization (SISH). For Ki-67
expression status, nuclear staining of at least 14% was considered to indicate a high level of expression. Breast cancers were divided into three molecular subtypes based on the immunohistochemical or SISH findings for ER, PR, HER2 as follows: luminal (hormone receptor positive and any of HER2 status), HER2-enriched (hormone receptor negative and HER2 positive), and triple-negative (hormonal receptor negative and HER2 negative) [23]. Tumors were divided into three histological groups: invasive ductal carcinoma, invasive lobular carcinoma, and others. The surgical margin status was classified as positive or close (<2 mm), or negative. Because frozen biopsy was routinely performed during surgery at our institution, immediate repeat excision was performed on the same day for patients showing a positive margin in the frozen biopsy. Only the final results of the surgical margin were analyzed. We reviewed the patients’ medical records to identify whether they received adjuvant chemotherapy, adjuvant radiation therapy, or adjuvant endocrine therapy. We also reviewed the TNM stage after surgery and the follow-up information from the medical records including imaging studies for each patient.

Statistical analyses

Breast cancer recurrence was defined as local recurrence (limited to the ipsilateral breast or chest wall), regional recurrence (ipsilateral axillary, infraclavicular, or supraclavicular lymph nodes), contralateral breast, or distant metastasis to other parts of the body. DFS and disease-specific survival (DSS) were calculated from the date of surgery to that of breast cancer recurrence, the date of death, the date last known to have no evidence of disease, or the date of the most recent follow-up. Patients without an event were censored at the date of the most recent follow-up, regardless of whether they were scheduled for future follow-up or they had been lost to follow-up.

The Cox proportional hazards model was used to determine the association between MR imaging kinetic features derived from CAD and DFS or DSS. The peak signal intensity and volumetric assessment of different kinetic components were compared to the clinical-pathological variables using a Student’s t-test and analysis of variance (ANOVA).

Statistical significance was set at \( P < .05 \). Variables with \( P < .05 \) on the univariate analysis were entered as the input variables for a multivariate model. All statistical analyses were performed by a dedicated statistician using R statistical software (version 3.2.4; R Foundation for Statistical Computing, Vienna, Austria).

Results

Patients characteristics and survival outcome

The mean follow-up time was 55.2 months (range, 5–72 months). There were 32 recurrences in 32 patients (7 local, 6 regional, 5 contralateral breasts, 14 distant) at a mean of 33.3 months (range, 5–72 months).

Of the 301 study lesions, 272 (90.4%) were invasive ductal carcinomas, 11 (3.7%) were invasive lobular carcinomas, and 18 (5.9%) were other types of carcinoma. Of the 18 other carcinomas, 5 were mucinous, 3 were mixed invasive ductal and mucinous, 3 were invasive apocrine, 3 were invasive micropapillary, 2 were medullary, 1 was adenoid cystic, and 1 was tubular. Among 301 patients, 59 (19.6%) patients underwent mastectomy and 242 (80.4%) patients received breast-conserving surgery. For resection margin, most were negative (80.1%) while 19.9% were close (<2mm) or positive.
Survival analysis: Univariate and multivariate

Univariate analysis of clinicopathological variables associated with DFS is presented in Table 1. Among the clinical-pathological variables, T2 stage (DFS hazard ratio, 2.053; \( P = .049 \)), N3 stage (DFS hazard ratio, 4.836; \( P = .005 \)), histologic grade 2 (DFS hazard ratio, 4.490; \( P = .048 \)), histologic grade 3 (DFS hazard ratio, 9.782; \( P = .002 \)), ER negativity (DFS hazard ratio, 5.243; \( P < .0001 \)), PR negativity (DFS hazard ratio, 4.402; \( P = .0001 \)), triple-negative subtype (DFS hazard ratio, 7.093; \( P < .0001 \)), and not receiving adjuvant endocrine therapy (DFS hazard ratio, 3.968; \( P = .0001 \)) were associated with worse DFS outcomes. With regard to the CAD-derived kinetic features, the mean peak enhancement value of the recurrence group was higher than that of the non-recurrence group (310.19% [median, 305%; interquartile range, 236–384.8%] vs 252.13% [median, 235%; interquartile range, 191–297%], respectively) and the higher peak signal enhancement (DFS hazard ratio, 1.004; \( P = .001 \)) was significantly associated with a worse DFS on univariate analysis (Figs 1 and 2; Table 2). Although the mean value of the washout component was higher in the recurrence group than non-recurrence group (39.19% [median, 40.5%; interquartile range, 24.50–54.25%] vs 38.08% [median, 34%; interquartile range, 15–60%], respectively), there was no statistically significant difference in DFS between the two groups (DFS hazard ratio, 1.001; \( P = .834 \)). The three kinetic curve patterns presented by CAD were not significantly different in DFS between the two groups (\( P > .05 \)).

Multivariate analysis revealed that higher peak enhancement (DFS hazard ratio, 1.004 [95% confidence interval [CI]: 1.001, 1.006]; \( P = .013 \)) and triple-negative subtype (DFS hazard ratio, 21.060 [95% CI: 2.675, 165.780]; \( P = .004 \)) were independently associated with worse DFS outcomes (Table 3). Survival analysis for DSS was not performed because there were only six deaths in our study population [24].

Correlation between MR kinetic parameters and clinical-pathological variables

The correlation between CAD-derived MR kinetic features with clinicopathological variables are presented in Table 4. Higher peak enhancement was significantly associated with a higher T stage, higher clinical stage, and a higher histologic grade. Pathologic diagnosis of invasive ductal carcinoma, higher histologic grade, and triple-negative subtype were significantly associated with a higher washout component on the delayed enhancement phase on DCE MR imaging. Higher histologic grade, ER negativity, PR negativity, and p53 positivity were associated with a higher mean percentage volume of rapid enhancement components on early phase enhancement. On the contrary, lower histologic grade, ER positivity, PR positivity, and p53 negativity were associated with a higher mean percentage volume of medium enhancement components on early phase enhancement. Persistent enhancement on delayed phase was seen in tumors with a lower histologic grade.

Discussion

Multivariate survival analysis revealed that patients with breast cancer who showed a higher peak enhancement (DFS hazard ratio, 1.004 [95% CI: 1.001, 1.006]; \( P = .013 \)) on DCE breast MR imaging and triple-negative subtype (DFS hazard ratio, 21.060 [95% CI: 2.675, 165.780]; \( P = .004 \)) had worse DFS. Higher peak enhancement was significantly associated with a higher T stage, higher clinical stage, and higher histological grade. Pathological diagnosis of invasive ductal carcinoma, higher histologic grade, and triple-negative subtype were significantly associated with a higher washout component on the delayed enhancement phase on DCE MR imaging. Our study showed that higher peak enhancement was associated with poorer DFS as
### Table 1. Univariate Cox proportional hazard analysis of clinicopathological variables with survival outcomes.

| Variables          | No. of patients (recurrence) | Hazard ratio | 95% CI       | P value |
|--------------------|-------------------------------|--------------|--------------|---------|
|                    | No (N = 269)                 | Yes (N = 32) |              |         |
| Mean age (years)   | 51.2 (28–80)                 | 49.5 (26–76) | 0.988        | 0.954, 1.023 | 0.497   |
|                    |                               |              |              |         |
| T stage            |                               |              |              |         |
| 1                  | 169 (62.8%)                  | 14 (43.8%)   | Reference    |         |
| 2                  | 90 (33.5%)                   | 16 (50.0%)   | 2.053        | 1.002, 4.207 | 0.049   |
| 3                  | 9 (3.3%)                     | 2 (6.3%)     | 2.777        | 0.631, 12.223 | 0.177   |
| 4                  | 1 (0.4%)                     | 0 (0%)       | 0            | 0.000, ∞     | 0.997   |
| N stage            |                               |              |              |         |
| 0                  | 170 (63.2%)                  | 17 (53.1%)   | Reference    |         |
| 1                  | 77 (28.6%)                   | 9 (28.1%)    | 1.153        | 0.514, 2.586 | 0.731   |
| 2                  | 16 (5.9%)                    | 2 (6.3%)     | 1.258        | 0.291, 5.444 | 0.759   |
| 3                  | 6 (2.2%)                     | 4 (12.5%)    | 4.836        | 1.626, 14.386 | 0.005   |
| Stage              |                               |              |              |         |
| 1                  | 126 (46.8%)                  | 10 (31.3%)   | Reference    |         |
| 2                  | 115 (42.8%)                  | 16 (50.0%)   | 1.667        | 0.756, 3.673 | 0.205   |
| 3                  | 28 (10.4%)                   | 6 (18.8%)    | 2.580        | 0.938, 7.100 | 0.066   |
| Pathologic type    |                               |              |              |         |
| IDC                | 242 (90.0%)                  | 30 (93.8%)   | Reference    |         |
| ILC                | 10 (3.7%)                    | 1 (3.1%)     | 0.850        | 0.116, 6.233 | 0.873   |
| Others             | 17 (6.3%)                    | 1 (3.1%)     | 0.663        | 0.090, 4.862 | 0.686   |
| Histologic grade   |                               |              |              |         |
| 1                  | 88 (32.7%)                   | 2 (6.3%)     | Reference    |         |
| 2                  | 114 (42.4%)                  | 13 (40.6%)   | 4.490        | 1.013, 19.896 | 0.048   |
| 3                  | 67 (24.9%)                   | 17 (53.1%)   | 9.782        | 2.260, 42.342 | 0.002   |
| ER                 |                               |              |              |         |
| Positive           | 202 (75.1%)                  | 11 (34.4%)   | Reference    |         |
| Negative           | 67 (24.9%)                   | 21 (65.6%)   | 5.243        | 2.527, 10.880 | <0.0001 |
| PR                 |                               |              |              |         |
| Positive           | 185 (68.8%)                  | 10 (31.2%)   | Reference    |         |
| Negative           | 84 (31.2%)                   | 22 (68.8%)   | 4.402        | 2.084, 9.299 | 0.0001  |
| HER2               |                               |              |              |         |
| Positive           | 59 (21.9%)                   | 5 (15.6%)    | Reference    |         |
| Negative           | 210 (78.1%)                  | 27 (84.4%)   | 1.511        | 0.582, 3.923 | 0.397   |
| p53                |                               |              |              |         |
| Positive           | 91 (33.8%)                   | 14 (43.8%)   | Reference    |         |
| Negative           | 178 (66.2%)                  | 18 (56.3%)   | 0.675        | 0.336, 1.357 | 0.270   |
| Molecular subtype  |                               |              |              |         |
| Luminal            | 203 (75.5%)                  | 12 (37.5%)   | Reference    |         |
| HER2-enriched      | 30 (11.2%)                   | 2 (6.3%)     | 1.160        | 0.260, 5.182 | 0.846   |
| Triple-negative    | 36 (13.4%)                   | 18 (56.3%)   | 7.093        | 3.412, 14.745 | <0.0001 |
| Ki-67              |                               |              |              |         |
| >14%               | 164 (61.0%)                  | 25 (78.1%)   | Reference    |         |
| ≤14%               | 105 (39.0%)                  | 7 (21.9%)    | 0.460        | 0.199, 1.063 | 0.069   |
| LVI                |                               |              |              |         |
| Present            | 86 (32.0%)                   | 14 (43.8%)   | Reference    |         |
| Absent             | 183 (68.0%)                  | 18 (56.3%)   | 0.609        | 0.303, 1.225 | 0.164   |

(Continued)
As well as tumor aggressiveness. In addition, higher washout component was representative of tumor aggressiveness.

Until now, most studies on MR kinetic features using CAD have focused on correlations with histopathologic findings. Leong et al. [18] found that a higher peak signal intensity was seen in ER-negative, PR-negative, and triple-negative tumors, compared to ER-positive, PR-positive, and non-triple-negative tumors. Kinetic features on DCE MR imaging are known to be dependent on the tumor perfusion flow, microvessel density, vascular permeability, and volume of extracellular-extravascular space composition [25–27]. Among CAD-derived kinetic parameters, peak enhancement is considered to reflect the concentration of the contrast agent in both intravascular and extravascular interstitial spaces [8]. In previous reports, high microvessel density and increased vascular permeability were associated with a higher nuclear grade [28], axillary lymph node metastasis, and distant metastasis [4, 21, 29]. Other studies have shown that peak enhancement was significantly greater among patients with lymph node metastasis and lymph node extracapsular extension [30, 31]. We believe that these results might explain the relationship between the peak enhancement on DCE MR imaging and poor prognosis.

Regarding delayed phase kinetic features, a washout kinetic pattern has been reported to correlate with a higher histologic grade, higher Ki-67 expression, increased vascular permeability, and HER2-enriched subtype [18, 32, 33]. In addition, a higher vascular permeability due to increased expression of vascular endothelial growth factor typically found in fast-growing tumors, may cause a higher washout component [8, 34]. Based on these prior results, we expected that a higher washout component on delayed phase enhancement might be associated with a poorer prognosis. In our study, a higher washout component on delayed phase enhancement was associated with the pathological diagnosis of invasive ductal carcinoma,

### Table 1. (Continued)

| Variables                      | No. of patients (recurrence) | Hazard ratio | 95% CI        | P value |
|--------------------------------|------------------------------|--------------|---------------|---------|
|                                | No (N = 269)                | Yes (N = 32) |               |         |
| Present                        | 54 (20.1%)                  | 7 (21.9%)    | Reference     |         |
| Absent                         | 215 (79.9%)                 | 25 (78.1%)   | 0.960         | 0.416, 2.220 | 0.924   |
| Operation method               |                              |              |               |         |
| Breast-conserving surgery      | 218 (81.0%)                 | 24 (75.0%)   | Reference     |         |
| Mastectomy                     | 51 (19.0%)                  | 8 (25.0%)    | 1.368         | 0.614, 3.045 | 0.443   |
| Resection margin               |                              |              |               |         |
| Negative                       | 215 (79.9%)                 | 26 (81.3%)   | Reference     |         |
| Close (<2 mm) or positive      | 54 (20.1%)                  | 6 (18.8%)    | 0.901         | 0.371, 2.189 | 0.817   |
| Adjuvant chemotherapy          |                              |              |               |         |
| No                             | 74 (27.5%)                  | 4 (12.5%)    | Reference     |         |
| Yes                            | 195 (72.5%)                 | 28 (87.5%)   | 0.412         | 0.145, 1.175 | 0.097   |
| Adjuvant radiation therapy     |                              |              |               |         |
| No                             | 38 (14.1%)                  | 6 (18.8%)    | Reference     |         |
| Yes                            | 231 (85.9%)                 | 26 (81.2%)   | 1.462         | 0.601, 3.559 | 0.403   |
| Adjuvant endocrine therapy     |                              |              |               |         |
| No                             | 70 (26.0%)                  | 19 (59.4%)   | Reference     |         |
| Yes                            | 199 (74.0%)                 | 13 (40.6%)   | 3.968         | 1.961, 8.065 | 0.0001  |

CI = confidence interval, IDC = invasive ductal carcinoma, ILC = invasive lobular carcinoma, ER = estrogen receptor, PR = progesterone receptor, HER2 = human epidermal growth factor receptor 2, LVI = Lymphovascular invasion, EIC = Extensive intraductal component

[https://doi.org/10.1371/journal.pone.0195756.t001](https://doi.org/10.1371/journal.pone.0195756.t001)
triple-negative subtype, and a higher histologic grade. However, contrary to expectations, there was no statistically significant association between the amount of washout component and survival outcomes. This result was different to that of a recent study; Kim et al. [35] evaluated the association between CAD-generated kinetic features and DFS of patients with primary operable breast cancer, reporting that a higher peak enhancement and washout component were associated with poorer DFS. When comparing with their study, profiles of CAD-generated kinetic features were very different. For example, the mean value of washout component in patients with recurrence was much lower than that of ours (10.38% vs. 39.19%). We speculate that these differences might be caused by using different machines or different protocols. Therefore, using same threshold of CAD-generated features obtained from other institution might be not feasible. Larger studies may be necessary to provide more comprehensive information.

In our study, none of the included morphological findings (shape, margin, internal enhancement) were significantly associated with DFS. Tumors with an irregular shape often occur in high grade breast cancer [36]. However, there was no significant difference in the current study.
In addition to MR imaging, the evaluation of dynamic patterns on breast imaging has also been applied to other modalities. Contrast-enhanced ultrasound (CEUS) imaging has been introduced for the evaluation of tumor kinetics and it enables determinations of the diffusion pattern and real-time quantification of the contrast agent [37–39]. Several quantitative parameters could be automatically calculated on CEUS from the time-intensity curve as follows: peak intensity; time to peak intensity; mean transit time; slope; rise time; and area under the time-intensity curve. CEUS facilitates the functional evaluation of microcirculation and hemodynamic characteristics without extravascular enhancement, which is seen in contrast-enhanced CT and MRI. However, there are no standardized criteria for differentiating between malignant and benign tumors because of different US machines and contrast agents. In addition, there is no general consensus about the methods of imaging acquisition, protocol of contrast agent injection, and ROI setting for time-intensity curve analysis. CEUS is not routinely used in clinical practice because it is difficult to scan an entire breast within a few minutes and time-consuming post-imaging analysis in real-time examinations [40]. Contrast enhanced spectral mammography (CESM) is currently increasing in use, which combines the relative...
ease, low cost, and practicality of mammography with the high sensitivity of MRI [41–43]. CESM uses intravenous contrast media to obtain the images of enhancing structures. However, dynamic enhancement pattern could not be shown because CESM only shows the existence of enhancement. In the present study, we evaluated the value of CAD-derived kinetic features and our results showed that they might have the potential to be used to characterize tumor aggressiveness and predict the patients' outcome.

We only included patients who underwent 1.5-T MR imaging because Jansen et al [44] demonstrated that kinetic curves might not be completely consistent across three different MR imaging systems with the same field strength (1.5-T). In another study, qualitative measures of curve shape were not consistent across different field strengths, even when the acquisition parameters were standardized; the maximum percent signal enhancement was significantly higher at 3 T than at 1.5 T [45, 46]. Further studies are required to investigate differences between various MR imagers.

Our study had some limitations. First, this study had a relatively short follow-up period (mean, 55.2 months). It is well known that women with ER-positive tumors remain at risk for late recurrences after primary treatment, which might partly account for the small number of patients with recurrence, making it difficult to observe a robust survival outcome [47]. Second,

### Table 2. Univariate Cox proportional hazard analysis of morphologic and kinetic features on MR imaging with survival outcomes.

| Variables                              | No. of patients (recurrence) | Hazard ratio | 95% CI     | P value |
|----------------------------------------|------------------------------|--------------|------------|---------|
|                                        | No (n = 269)                | Yes (n = 32) |            |         |
| Mass shape                             |                              |              |            |         |
| Oval                                   | 40 (14.9%)                  | 5 (15.6%)    | Reference  |         |
| Round                                  | 27 (10.0%)                  | 3 (9.4%)     | 0.926      | 0.221, 3.875 | 0.916 |
| Irregular                               | 202 (75.1%)                 | 24 (75.0%)   | 1.020      | 0.389, 2.673 | 0.968 |
| Mass margin                            |                              |              |            |         |
| Circumscribed                          | 25 (9.3%)                   | 3 (9.4%)     | Reference  |         |
| Not circumscribed                      | 244 (90.7%)                 | 29 (90.6%)   | 1.072      | 0.327, 3.520 | 0.909 |
| Mass internal enhancement              |                              |              |            |         |
| Homogeneous                            | 32 (11.9%)                  | 2 (6.2%)     | Reference  |         |
| Heterogeneous                          | 204 (75.8%)                 | 22 (68.8%)   | 1.829      | 0.430, 7.779 | 0.414 |
| Rim enhancement                        | 33 (123%)                   | 8 (25.0%)    | 4.004      | 0.850, 18.858 | 0.079 |
| Peak signal intensity (%)              | 252.13 (77–986)             | 310.19 (132–559) | 1.004 | 1.002, 1.006 | 0.001 |
| Early phase enhancement §              |                              |              |            |         |
| Medium (%)                             | 7.96                        | 4.00         | 0.980      | 0.948, 1.013 | 0.234 |
| Rapid (%)                              | 92.08                       | 96.03        | 1.020      | 0.987, 1.054 | 0.236 |
| Delayed phase enhancement §            |                              |              |            |         |
| Persistent (%)                         | 21.22                       | 19.3         | 0.997      | 0.982, 1.013 | 0.732 |
| Plateau (%)                            | 40.69                       | 41.56        | 1.001      | 0.983, 1.021 | 0.886 |
| Washout (%)                            | 38.08                       | 39.19        | 1.001      | 0.989, 1.014 | 0.834 |
| Kinetic curve presented by CAD         |                              |              |            |         |
| Type 1 (delayed persistent enhancement pattern) | 2 (0.7%)                   | 0 (0%)       | Reference  |         |
| Type 2 (delayed plateau enhancement pattern) | 13 (4.8%)                  | 2 (6.3%)     | 407285.2191 | 0, Inf | 0.997 |
| Type 3 (delayed washout enhancement pattern) | 254 (94.4%)                | 30 (93.7%)   | 3274787.6777 | 0, Inf | 0.997 |

* Numbers represent the mean values with ranges
$ Numbers represent percentages
CI = confidence interval

https://doi.org/10.1371/journal.pone.0195756.t002
our results might be difficult to generalize because they were based on a single center, mass lesions, a single imaging protocol, and single CAD system. Third, we could not evaluate inter- or intra-observer agreement of MR kinetic values because the CAD reports were stored prospectively. However, the same results are likely between observers given that we used a standardized ROI policy for choosing image slices that revealed the largest diameter and only mass lesions (non-mass enhancements were excluded). In our experience, significant segmentation differences are markedly decreased in mass lesions compared with non-mass enhancement lesions. In addition, the purpose of our study was not to evaluate the diagnostic accuracy of CAD, but observational survival analysis. Fourth, although these factors might have affected CAD-derived values, we did not consider the effect of the patient’s motion or field inhomogeneity. Finally, of the 32 recurrences, 2 recurrences were detected within the first 6 months from the initial diagnosis, and these could have been due to residual disease.

In conclusion, our findings suggested that preoperative MR imaging kinetic features assessed using a commercially available CAD have the potential to predict survival outcomes. Patients with breast cancer who showed a higher peak enhancement on breast MR imaging may exhibit a worse DFS. In addition, peak enhancement and volumetric analysis of the early and delayed phase enhancements of breast cancers showed correlation with tumor stage, pathological findings, and histological grade, which are indicators of tumor aggressiveness.

| Variable                  | $P$ value | Disease-free survival |
|---------------------------|-----------|-----------------------|
|                           |           | Hazard ratio | 95% CI       |
| Peak enhancement          | 0.013     | 1.004       | 1.001, 1.006 |
| T stage                   |           | Reference    |              |
| 1                         |           |             |              |
| 2                         | 0.220     | 1.669       | 0.737, 3.779 |
| 3                         | 0.215     | 3.046       | 0.524, 17.698|
| 4                         | 0.998     | 0.000       | 0.000, $\infty$ |
| N stage                   |           | Reference    |              |
| 0                         |           |             |              |
| 1                         | 0.591     | 1.267       | 0.534, 3.004 |
| 2                         | 0.836     | 0.851       | 0.185, 3.914 |
| 3                         | 0.081     | 3.040       | 0.872, 10.598|
| Histologic grade          |           | Reference    |              |
| 1                         |           |             |              |
| 2                         | 0.131     | 3.227       | 0.704, 14.784|
| 3                         | 0.176     | 3.162       | 0.596, 16.775|
| Molecular subtype         |           | Reference    |              |
| Luminal                   |           |             |              |
| HER2-enriched             | 0.306     | 3.538       | 0.314, 39.828|
| Triple-negative           | 0.004     | 21.060      | 2.675, 165.780|
| Adjuvant endocrine therapy|           | Reference    |              |
| No                        | 0.263     | 3.282       | 0.409, 26.305|
| Yes                       |           |             |              |

CI = confidence interval, HER2 = human epidermal growth factor receptor 2

https://doi.org/10.1371/journal.pone.0195756.t003
Table 4. Relationship between MR imaging kinetic features and various clinicopathological findings.

| Variable       | Peak signal intensity | Early enhancement phase | Delayed enhancement phase |
|----------------|-----------------------|-------------------------|---------------------------|
|                | Value (%)             | Medium (%)              | Rapid (%)                 | Persistent (%)            | Plateau (%) | Washout (%) | P       |
| T stage        | <0.0001               | 0.865                   | 0.865                     | 0.615                     | 0.149       | 0.611       |
| 1              | 235.634               | 8.139                   | 91.896                    | 21.980                    | 40.783       | 37.208       |
| 2              | 293.528               | 6.680                   | 93.359                    | 20.141                    | 39.509       | 40.371       |
| 3              | 297.818               | 6.418                   | 93.636                    | 15.273                    | 52.727       | 32.182       |
| 4              | 239.000               | 0.000                   | 100.000                   | 1.000                     | 45.000       | 54           |
| N stage        | 0.097                 | 0.971                   | 0.971                     | 0.373                     | 0.950       | 0.412       |
| 0              | 248.460               | 7.264                   | 92.775                    | 21.979                    | 40.481       | 37.530       |
| 1              | 278.151               | 7.687                   | 92.337                    | 17.514                    | 40.921       | 41.584       |
| 2              | 245.833               | 9.171                   | 90.889                    | 25.500                    | 41.667       | 32.889       |
| 3              | 294.200               | 8.360                   | 91.700                    | 25.100                    | 43.700       | 31.000       |
| Stage          | 0.0003                | 0.797                   | 0.801                     | 0.620                     | 0.615       | 0.366       |
| 1              | 232.765               | 7.512                   | 92.529                    | 21.882                    | 40.596       | 37.508       |
| 2              | 283.611               | 7.097                   | 92.931                    | 19.560                    | 40.238       | 40.216       |
| 3              | 262.971               | 9.317                   | 90.733                    | 23.1765                   | 43.6471      | 33.1471      |
| Pathologic type| 0.585                 | 0.401                   | 0.407                     | 0.054                     | 0.485       | 0.015       |
| IDC            | 259.768               | 7.106                   | 92.927                    | 19.950                    | 40.427       | 39.615       |
| ILC            | 262.273               | 10.706                  | 89.455                    | 32.636                    | 46.727       | 20.473       |
| Others         | 233.778               | 12.087                  | 87.944                    | 30.056                    | 42.556       | 27.556       |
| Histologic grade| 0.032                | 0.029                   | 0.030                     | 0.019                     | 0.299       | 0.006       |
| 1              | 234.644               | 8.908                   | 91.144                    | 26.713                    | 41.589       | 31.701       |
| 2              | 266.126               | 9.327                   | 90.709                    | 19.527                    | 41.939       | 38.552       |
| 3              | 271.833               | 9.356                   | 96.667                    | 17.169                    | 38.179       | 44.610       |
| ER             | 0.661                 | 0.039                   | 0.040                     | 0.247                     | 0.181       | 0.053       |
| Positive       | 256.612               | 8.461                   | 91.202                    | 22.035                    | 41.686       | 36.259       |
| Negative       | 262.386               | 4.376                   | 95.648                    | 18.553                    | 38.602       | 42.878       |
| PR             | 0.505                 | 0.038                   | 0.040                     | 0.344                     | 0.273       | 0.110       |
| Positive       | 255.364               | 9.035                   | 91.010                    | 21.972                    | 41.632       | 36.362       |
| Negative       | 263.717               | 4.776                   | 95.245                    | 19.262                    | 39.226       | 41.564       |
| HER2           | 0.085                 | 0.401                   | 0.406                     | 0.560                     | 0.206       | 0.189       |
| Positive       | 278.141               | 5.944                   | 94.078                    | 19.636                    | 38.234       | 42.126       |
| Negative       | 252.949               | 7.965                   | 92.076                    | 21.391                    | 41.473       | 37.132       |
| p53            | 0.376                 | 0.026                   | 0.027                     | 0.064                     | 0.128       | 0.550       |
| Positive       | 265.543               | 4.550                   | 95.476                    | 17.568                    | 42.962       | 39.467       |
| Negative       | 254.429               | 9.134                   | 90.908                    | 22.866                    | 39.618       | 37.512       |
| Molecular subtype| 0.765                | 0.096                   | 0.098                     | 0.210                     | 0.149       | 0.016       |
| Luminal        | 255.586               | 8.879                   | 91.163                    | 22.133                    | 41.903       | 35.945       |
| HER2 enriched  | 267.188               | 4.025                   | 96.000                    | 14.225                    | 35.500       | 50.284       |
| Triple-negative| 263.870               | 4.264                   | 95.759                    | 20.604                    | 39.463       | 39.985       |
| Ki-67          | 0.177                 | 0.086                   | 0.087                     | 0.103                     | 0.955       | 0.163       |
| >14%           | 264.524               | 6.236                   | 93.799                    | 19.301                    | 40.831       | 39.866       |
| ≤14%           | 247.813               | 9.72                    | 90.313                    | 23.914                    | 40.707       | 35.373       |
| LVI            | 0.143                 | 0.056                   | 0.057                     | 0.167                     | 0.023       | 0.747       |
| Present        | 270.710               | 4.875                   | 95.160                    | 18.341                    | 44.150       | 37.482       |
| Absent         | 252.134               | 8.859                   | 91.179                    | 22.349                    | 39.110       | 38.548       |
| EIC            | 0.056                 | 0.759                   | 0.760                     | 0.851                     | 0.021       | 0.081       |
| Present        | 251.295               | 6.934                   | 93.099                    | 21.528                    | 45.574       | 32.820       |

(Continued)
Table 4. (Continued)

| Variable                  | Peak signal intensity | Early enhancement phase | Delayed enhancement phase |
|---------------------------|-----------------------|-------------------------|---------------------------|
|                           | Value (%)  | Medium (%)  | Rapid (%)  | Persistent (%)  | Plateau (%)  | Washout (%)  | P  |
| Absent                    | 260.088    | 7.688       | 92.350     | 20.888           | 39.568       | 39.560       |    |
| Operation method          | 0.055      | 0.069       | 0.069      | 0.640            | 0.339        | 0.303        |    |
| Breast-conserving surgery | 252.649    | 6.653       | 93.384     | 20.702           | 40.290       | 38.984       |    |
| Mastectomy                | 281.509    | 11.152      | 88.881     | 22.312           | 42.814       | 34.953       |    |
| Mass shape                | 0.056      | 0.856       | 0.855      | 0.822            | 0.066        | 0.188        |    |
| Oval                      | 247.111    | 7.557       | 92.467     | 19.409           | 35.978       | 44.667       |    |
| Round                     | 219.933    | 9.169       | 90.867     | 22.870           | 37.540       | 39.567       |    |
| Irregular                 | 265.628    | 7.314       | 92.726     | 21.092           | 42.173       | 36.723       |    |
| Mass margin               | 0.569      | 0.981       | 0.972      | 0.623            | 0.802        | 0.795        |    |
| Circumscribed             | 247.643    | 7.610       | 92.393     | 23.089           | 39.964       | 36.929       |    |
| Not circumscribed         | 259.399    | 7.528       | 92.513     | 20.805           | 40.869       | 38.324       |    |
| Mass internal enhancement | 0.120      | 0.836       | 0.839      | 0.201            | 0.679        | 0.094        |    |
| Homogeneous               | 231.029    | 6.335       | 93.677     | 14.732           | 38.324       | 46.973       |    |
| Heterogeneous             | 258.372    | 7.871       | 92.168     | 22.260           | 41.227       | 36.510       |    |
| Rim enhancement           | 280.561    | 6.678       | 93.366     | 19.383           | 40.390       | 40.195       |    |

IDC = invasive ductal carcinoma, ILC = invasive lobular carcinoma, ER = estrogen receptor, PR = progesterone receptor, HER2 = human epidermal growth factor receptor 2, LVI = Lymphovascular invasion, EIC = Extensive intraductal component

https://doi.org/10.1371/journal.pone.0195756.t004

Supporting information

S1 Dataset. Detailed characteristics of patients.
(XLS)

Author Contributions

Conceptualization: Eun Sook Ko, Jeong Eon Lee.

Data curation: Sang Yu Nam, Yaeji Lim, Boo-Kyung Han, Eun Young Ko, Ji Soo Choi.

Formal analysis: Sang Yu Nam, Eun Sook Ko, Ji Soo Choi.

Investigation: Sang Yu Nam, Eun Sook Ko, Yaeji Lim.

Methodology: Sang Yu Nam, Eun Sook Ko, Yaeji Lim, Ji Soo Choi, Jeong Eon Lee.

Resources: Ji Soo Choi.

Supervision: Jeong Eon Lee.

Validation: Yaeji Lim, Jeong Eon Lee.

Writing – original draft: Sang Yu Nam, Eun Sook Ko.

Writing – review & editing: Sang Yu Nam, Eun Sook Ko, Yaeji Lim, Boo-Kyung Han, Eun Young Ko, Ji Soo Choi, Jeong Eon Lee.

References

1. Houssami N, Ciatto S, Macaskill P, Lord SJ, Warren RM, Dixon JM, et al. Accuracy and surgical impact of magnetic resonance imaging in breast cancer staging: systematic review and meta-analysis in detection of multifocal and multicentric cancer. J Clin Oncol. 2008; 26(19):3248–58. Epub 2008/05/14. https://doi.org/10.1200/JCO.2007.15.2108 PMID: 18474876.
2. Warner E, Messersmith H, Causer P, Eisen A, Shumak R, Plewes D. Systematic review: using magnetic resonance imaging to screen women at high risk for breast cancer. Ann Intern Med. 2008; 148(9):671–9. Epub 2008/05/07. PMID: 18458280.

3. Kuhl CK, Micelcareck P, Klaschik S, Leutner C, Wardemann E, Gieseke J, et al. Dynamic breast MR imaging: are signal intensity time course data useful for differential diagnosis of enhancing lesions? Radiology. 1999; 211(1):101–10. Epub 1999/04/06. https://doi.org/10.1148/radiology.211.1.r99ap38101 PMID: 10184599.

4. Tuncbilek N, Tokati F, Altaner S, Sezer A, Ture M, Omurlu IK, et al. Prognostic value DCE-MRI parameters in predicting factor disease free survival and overall survival for breast cancer patients. Eur J Radiol. 2012; 81(5):863–7. Epub 2011/03/15. https://doi.org/10.1016/j.ejrad.2011.02.021 PMID: 21398061.

5. Turetschek K, Huber S, Floyd E, Helbich T, Roberts TP, Shames DM, et al. MRI imaging characterization of microvessels in experimental breast tumors by using a particulate contrast agent with histopathologic correlation. Radiology. 2001; 218(2):562–9. Epub 2001/02/13. https://doi.org/10.1148/radiology.218.2.r01fe37562 PMID: 11161179.

6. Chaudhury B, Zhou M, Goldgof DB, Hall LO, Gatenby RA, Gillies RJ, et al. Heterogeneity in intratumoral regions with rapid gadolinium washout correlates with estrogen receptor status and nodal metastasis. Journal of magnetic resonance imaging: JMRI. 2015; 42(5):1421–30. Epub 2015/04/18. https://doi.org/10.1002/jmri.24921 PMID: 25884277; PubMed Central PMCID: PMCPMC5017794.

7. Rahbar H, Partridge SC. Multiparametric MR Imaging of Breast Cancer. Magnetic resonance imaging clinics of North America. 2016; 24(1):223–38. Epub 2015/11/29. https://doi.org/10.1016/j.mric.2015.08.012 PMID: 26613883; PubMed Central PMCID: PMCPMC4672390.

8. Tofts PS, Brix G, Buckley DL, Evelhoch JL, Henderson E, Knopp MV, et al. Estimating kinetic parameters from dynamic contrast-enhanced T1-weighted MRI of a diffusible tracer: standardized quantities and symbols. Journal of magnetic resonance imaging: JMRI. 1999; 10(3):223–32. Epub 1999/10/03. PMID: 10508281.

9. Sourbron SP, Buckley DL. On the scope and interpretation of the Tofts models for DCE-MRI. Magnetic resonance in medicine. 2011; 66(3):735–45. Epub 2011/03/09. https://doi.org/10.1002/mrm.22861 PMID: 21384424.

10. Vajuvalli NN, Chikkemenahally DK, Nayak KN, Bhosale MG, Geethanath S. The Tofts model in frequency domain: fast and robust determination of pharmacokinetic maps for dynamic contrast enhancement MRI. Physics in medicine and biology. 2016; 61(24):8462–75. Epub 2016/11/16. https://doi.org/10.1088/0031-9155/61/24/8462 PMID: 27845923.

11. Balthzer PA, Freiberg C, Beger S, Vag T, Dietzel M, Herzog AB, et al. Clinical MR-mammography: are computer-assisted methods superior to visual or manual measurements for curve type analysis? A systematic approach. Acad Radiol. 2009; 16(9):1070–6. Epub 2009/06/16. https://doi.org/10.1016/j.acra.2009.03.017 PMID: 19523854.

12. Lehman CD, Peacock S, DeMartini WB, Chen X. A new automated software system to evaluate breast MR examinations: improved specificity without decreased sensitivity. AJR Am J Roentgenol. 2006; 187(1):51–6. Epub 2006/06/24. https://doi.org/10.2214/AJR.05.0269 PMID: 16794155.

13. Meinel LA, Stolpen AH, Berbaum KS, Fajardo LL, Reinhardt JM. Breast MRI lesion classification: improved performance of human readers with a backpropagation neural network computer-aided diagnosis (CAD) system. Journal of magnetic resonance imaging: JMRI. 2007; 25(1):89–95. Epub 2006/12/13. https://doi.org/10.1002/jmri.20794 PMID: 17154399.

14. Dromain C, Boyer B, Ferre R, Canale S, Delaloge S, Balleyguier C. Computed-aided diagnosis (CAD) in the detection of breast cancer. Eur J Radiol. 2013; 82(3):417–23. Epub 2012/09/04. https://doi.org/10.1016/j.ejrad.2012.03.005 PMID: 22939365.

15. Song SE, Seo BK, Cho KR, Woo OH, Son GS, Kim C, et al. Computer-aided detection (CAD) system for breast MRI in assessment of local tumor extent, nodal status, and multifocality of invasive breast cancers: preliminary study. Cancer Imaging. 2015; 15:1. Epub 2015/04/19. https://doi.org/10.1186/s40644-015-0036-2 PMID: 25888983; PubMed Central PMCID: PMCPMC4344797.

16. Bhooshan N, Giger ML, Jansen SA, Li H, Lan L, Newstead GM. Cancerous breast lesions on dynamic contrast-enhanced MR images: computerized characterization for image-based prognostic markers. Radiology. 2010; 254(3):680–90. Epub 2010/02/04. https://doi.org/10.1148/radiol.09090838 PMID: 20123903; PubMed Central PMCID: PMCPMC2826695.

17. Meeuwis C, van de Ven SM, Stapper G, Fernandez Gallardo AM, van den Bosch MA, Mali WP, et al. Computer-aided detection (CAD) for breast MRI: evaluation of efficacy at 3.0 T. European radiology. 2010; 20(3):522–8. Epub 2009/09/04. https://doi.org/10.1007/s00330-009-1573-5 PMID: 19727750; PubMed Central PMCID: PMCPMC2822230.
18. Leong LC, Gombos EC, Jagadeesan J, Fook-Chong SM. MRI kinetics with volumetric analysis in correlation with hormonal receptor subtypes and histologic grade of invasive breast cancers. AJR Am J Roentgenol. 2015; 204(3):W348–56. Epub 2015/02/26. https://doi.org/10.2214/AJR.13.11486 PMID: 25714321; PubMed Central PMCID: PMC4851553.

19. Yi A, Cho N, Im SA, Chang JM, Kim SJ, Moon HG, et al. Survival outcomes of breast cancer patients who receive neoadjuvant chemotherapy: association with dynamic contrast-enhanced MR imaging with computer-aided evaluation. Radiology. 2013; 268(3):662–72. Epub 2013/04/18. https://doi.org/10.1148/radiol.13121801 PMID: 23592770.

20. Dietzel M, Zoubi R, Vag T, Gajda M, Runnebaum IB, Kaiser WA, et al. Association between survival in patients with primary invasive breast cancer and computer-aided MRI. Journal of magnetic resonance imaging: JMRI. 2013; 37(1):146–55. Epub 2012/09/27. https://doi.org/10.1002/jmri.23812 PMID: 23011784.

21. Baltzer PA, Zoubi R, Burmeister HP, Gajda M, Camara O, Kaiser WA, et al. Computer-aided analysis of MR-mammography reveals association between contrast enhancement and occurrence of distant metastasis. Technol Cancer Res Treat. 2012; 11(6):553–60. Epub 2012/05/10. https://doi.org/10.7785/tcrt.2012.500266 PMID: 22568630.

22. American College of Radiology. Breast imaging reporting and data system (BI-RADS). 5th ed: VA: American College of Radiology; 2013.

23. Blaschke E, Abe H. MRI phenotype of breast cancer: Kinetic assessment for molecular subtypes. Journal of magnetic resonance imaging: JMRI. 2015; 42(4):320–4. Epub 2015/03/12. https://doi.org/10.1002/jmri.24898 PMID: 25759673.

24. Zwiener I, Blettner M, Hommel G. Survival analysis: part 15 of a series on evaluation of scientific publications. Dtsch Arztebl Int. 2011; 108(10):163–9. Epub 2011/04/09. https://doi.org/10.3238/arztebl.2010.0163 PMID: 21475574; PubMed Central PMCID: PMC3071962.

25. Stomper PC, Winston JS, Herman S, Klippstein DL, Arredondo MA, Blumensohn LE. Angiogenesis and dynamic MR imaging gadolinium enhancement of malignant and benign breast lesions. Breast cancer research and treatment. 1997; 45(1):39–46. Epub 1997/08/01. PMID: 9285115.

26. Zahra MA, Hollingsworth KG, Sala E, Lomas DJ, Tan LT. Dynamic contrast-enhanced MRI as a predictor of tumour response to radiotherapy. The Lancet Oncology. 2007; 8(1):63–74. Epub 2007/01/02. https://doi.org/10.1016/S1470-2045(06)71012-9 PMID: 17196512.

27. Choi WW, Lewis MM, Lawson D, Yin-Goen Q, Birdsong GG, Cotsonis GA, et al. Angiogenic and lymphangiogenic microvessel density in breast carcinoma: correlation with clinicopathologic parameters and VEGF-family gene expression. Modern pathology: an official journal of the United States and Canadian Academy of Pathology, Inc. 2005; 18(1):143–52. Epub 2004/08/07. https://doi.org/10.1038/modpathol.3800253 PMID: 15297858.

28. Weidner N, Semple JP, Welch WR, Folkman J. Tumor angiogenesis and metastasis—correlation in invasive breast carcinoma. The New England journal of medicine. 1991; 324(1):1–8. Epub 1991/01/03. https://doi.org/10.1056/NEJM199101033240101 PMID: 1701519.

29. Loiselle CR, Eby PR, Peacock S, Kim JN, Lehman CD. Dynamic contrast-enhanced magnetic resonance imaging and invasive breast cancer: primary lesion kinetics correlated with auxiliary lymph node extracapsular extension. Journal of magnetic resonance imaging: JMRI. 2011; 33(1):96–101. Epub 2010/12/25. https://doi.org/10.1002/jmri.22389 PMID: 21182126.

30. Loiselle CR, Eby PR, DeMartini WB, Peacock S, Bittner N, Lehman CD, et al. Dynamic contrast-enhanced MRI kinetics of invasive breast cancer: a potential prognostic marker for radiation therapy. International journal of radiation oncology, biology, physics. 2010; 76(5):1314–9. Epub 2009/07/17. https://doi.org/10.1016/j.ijrobp.2009.03.053 PMID: 19604652.

31. Lee SH, Cho N, Kim SJ, Cha JH, Cho KS, Ko ES, et al. Correlation between high resolution dynamic MR features and prognostic factors in breast cancer. Korean J Radiol. 2008; 9(1):10–8. Epub 2008/02/07. https://doi.org/10.3348/kjr.2008.9.1.10 PMID: 18253071; PubMed Central PMCID: PMCPMC2627175.

32. Su MY, Cheung YC, Fruehauf JP, Yu H, Nalcioolu O, Mechetner E, et al. Correlation of dynamic contrast enhancement MRI parameters with microvessel density and VEGF for assessment of angiogenesis in breast cancer. Journal of magnetic resonance imaging: JMRI. 2003; 18(4):467–77. Epub 2003/09/26. https://doi.org/10.1002/jmri.10380 PMID: 14508784.

33. Dvorak HF, Brown LF, Detmar M, Dvorak AM. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol. 1995; 146(5):1029–39. Epub 1995/05/01. PMID: 7538264; PubMed Central PMCID: PMC1869291.

MR kinetic features assessed using computer-aided diagnosis in patients with breast cancer.
35. Kim JJ, Kim JY, Kang HJ, Shin JK, Kang T, Lee SW, et al. Computer-aided Diagnosis-generated Kinetic Features of Breast Cancer at Preoperative MR Imaging: Association with Disease-free Survival of Patients with Primary Operable Invasive Breast Cancer. Radiology. 2017; 284(1):45–54. Epub 2017/03/03. https://doi.org/10.1148/radiol.2017162079 PMID: 28253106.

36. Huang J, Yu J, Peng Y. Association between dynamic contrast enhanced MRI imaging features and WHO histopathological grade in patients with invasive ductal breast cancer. Oncol Lett. 2016; 11(5):3522–6. Epub 2016/04/29. https://doi.org/10.3892/ol.2016.4422 PMID: 27123145; PubMed Central PMCID: PMC4840852.

37. Wan CF, Du J, Fang H, Li FH, Zhu JS, Liu Q. Enhancement patterns and parameters of breast cancers at contrast-enhanced US: correlation with prognostic factors. Radiology. 2012; 262(2):450–9. Epub 2012/01/28. https://doi.org/10.1148/radiol.11110789 PMID: 22282183.

38. Leng X, Huang G, Ma F, Yao L. Regional Contrast-Enhanced Ultrasonography (CEUS) Characteristics of Breast Cancer and Correlation with Microvessel Density (MVD). Medical science monitor: international medical journal of experimental and clinical research. 2017; 23:3429–36. Epub 2017/07/15. https://doi.org/10.12659/MSM.901734 PMID: 28708818; PubMed Central PMCID: PMCPMC5523962.

39. Zhao YX, Liu S, Hu YB, Ge YY, Lv DM. Diagnostic and prognostic values of contrast-enhanced ultrasound in breast cancer: a retrospective study. Oncotargets and therapy. 2017; 10:1123–9. Epub 2017/03/07. https://doi.org/10.2147/OTT.S124134 PMID: 28260926; PubMed Central PMCID: PMCPMC5328613.

40. Liu H, Jiang YX, Liu JB, Zhu QL, Sun Q. Evaluation of breast lesions with contrast-enhanced ultrasound using the microvascular imaging technique: initial observations. Breast (Edinburgh, Scotland). 2008; 17(5):532–9. Epub 2008/06/07. https://doi.org/10.1016/j.breast.2008.04.004 PMID: 18534851.

41. Fallenberg EM, Dromain C, Diekmann F, Engelken F, Krohn M, Singh JM, et al. Contrast-enhanced spectral mammography versus MRI: Initial results in the detection of breast cancer and assessment of tumour size. European radiology. 2014; 24(1):256–64. Epub 2013/09/21. https://doi.org/10.1007/s00330-013-3007-7 PMID: 24048724.

42. Lobbes MB, Lalji U, Houwers J, Nijssen EC, Nelemans PJ, van Roozendael L, et al. Contrast-enhanced spectral mammography in patients referred from the breast cancer screening programme. European radiology. 2014; 24(7):1668–76. Epub 2014/04/04. https://doi.org/10.1007/s00330-014-3154-5 PMID: 24696228.

43. Tennant SL, James JJ, Cornford EJ, Chen Y, Burrell HC, Hamilton LJ, et al. Contrast-enhanced spectral mammography improves diagnostic accuracy in the symptomatic setting. Clinical radiology. 2016; 71(11):1148–55. Epub 2016/05/09. https://doi.org/10.1016/j.crad.2016.05.009 PMID: 27296475.

44. Jansen SA, Shimauchi A, Zak L, Fan X, Wood AM, Karczmars G, et al. Kinetic curves of malignant lesions are not consistent across MRI systems: need for improved standardization of breast dynamic contrast-enhanced MRI acquisition. AJR Am J Roentgenol. 2009; 193(3):832–9. Epub 2009/08/22. https://doi.org/10.2214/AJR.08.2025 PMID: 19696299; PubMed Central PMCID: PMCPMC2938789.

45. Pineda FD, Medved M, Fan X, Ivancevic MK, Abe H, Shimauchi A, et al. Comparison of dynamic contrast-enhanced MRI parameters of breast lesions at 1.5 and 3.0 T: a pilot study. Br J Radiol. 2015; 88(1049):20150021. Epub 2015/03/19. https://doi.org/10.1259/bjr.20150021 PMID: 25785918; PubMed Central PMCID: PMCPMC4628483.

46. Kuhl CK, Jost P, Morakabbati N, Zivanovic O, Schild HH, Gieseke J. Contrast-enhanced MR imaging of the breast at 3.0 and 1.5 T in the same patients: initial experience. Radiology. 2006; 239(3):666–76. Epub 2006/03/22. https://doi.org/10.1148/radiol.2392050509 PMID: 16549623.

47. Saphner T, Tormey DC, Gray R. Annual hazard rates of recurrence for breast cancer after primary therapy. J Clin Oncol. 1996; 14(10):2738–46. Epub 1996/10/01. https://doi.org/10.1200/JCO.1996.14.10.2738 PMID: 8874335.